Health Catalyst (NASDAQ:HCAT – Get Free Report) is set to issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.
Health Catalyst (NASDAQ:HCAT – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $74.72 million for the quarter, compared to analysts’ expectations of $74.81 million. Health Catalyst had a negative net margin of 35.56% and a negative return on equity of 11.86%. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Health Catalyst Price Performance
Shares of NASDAQ HCAT opened at $7.63 on Wednesday. The company’s fifty day moving average is $6.63 and its 200-day moving average is $7.48. Health Catalyst has a twelve month low of $5.45 and a twelve month high of $14.37.
Insider Buying and Selling at Health Catalyst
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on HCAT shares. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research report on Wednesday, April 10th. Wells Fargo & Company reduced their price target on shares of Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, May 10th. Piper Sandler reduced their price target on shares of Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a research report on Thursday, June 6th. Evercore ISI dropped their price objective on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $11.00 price objective on shares of Health Catalyst in a report on Tuesday, May 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.91.
View Our Latest Research Report on Health Catalyst
Health Catalyst Company Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Featured Articles
- Five stocks we like better than Health Catalyst
- What is the Nikkei 225 index?
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- With Risk Tolerance, One Size Does Not Fit All
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Oilfield Infrastructure Stock Soars Over 50% on Bold Acquisition
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.